Background and aims The successful application of IL-17 inhibitors in a number of chronic inflammatory diseases has increased interest for the role of IL-17 in other conditions. We investigated the clinical associations for the predominant family member IL-17A in patients with Systemic Lupus Erythematosus (SLE).
Methods Cross-sectional study of SLE patients (n=102, age 49, 86% female) recruited from a regional registry. IL-17A levels were determined by immunoassay, disease activity by SLEDAI-2K and cumulative damage by SLICC-DI scores. Non-parametric techniques were used to examine the association between IL-17A and disease activity, autoantibody profiles and damage development in SLE patients and for comparisons with healthy controls (n=31).
Results SLE patients had higher IgG levels, lower T cell and B cell counts, but median IL-17A levels did not differ from controls (28.4 vs. 28.4 pg/ml, p=0.9).
In SLE patients, IL-17A levels did not correlate with SLEDAI-2K or SDI, but were inversely related with systolic blood pressure (r=−0.31, p=0.02), years smoking (r=−0.23, p<0.001), cumulative heart (r=−0.24, p=0.03) and malignancy damage (r=−0.18, p=0.06).
Serological correlations for IL-17A existed with levels of IgG (r=0.21, p=0.05), hs-CRP levels (r=0.28, p<0.01), proteinuria (r=0.64, p=0.004) and pre-albumen (r=−0.22, p=0.03).
Longitudinal data showed only modest fluctuations in 17A levels, unrelated to SLEDAI-2K
Conclusions These data indicate that while IL-17A participates in the inflammatory process in SLE, it also seems to serve a protective purpose in reducing heart disease and cancer in SLE. This dual role is consistent with experimental and clinical data and raises concerns about inhibting IL-17 in SLE patients.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.